A subset of patients with KRAS proto‐oncogene (KRAS)/tumor protein p53 (TP53) mutant NSCLC were shown to be characterized by increased expression of PD‐L1 in tumor cells, increased TMB, and a higher degree of tumor infiltration by CD8+ T cells, which led to improved clinical outcomes.19 This evidence concerns the gene TP53 and neoplasm.